---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-028350"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-14T00:46:55.446564+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Orthofix cuts credit facility to $175M, amends EBITDA addbacks

## Summary
- Credit facility reduced from $300M to $175M; interest rate increased in certain circumstances.
- Maturity unchanged at October 25, 2024; $51M currently outstanding.
- Amended EBITDA calculation allows certain expense addbacks and higher foreign subsidiary EBITDA share from Q1 2023.
- Orthofix pledged ownership interest in Italian subsidiary Orthofix S.r.l. as additional collateral.

## SEC filing metadata
- accession: 0000950170-23-028350
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017023028350/0000950170-23-028350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017023028350/ofix-20230613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-028350
- JSON: https://secwatch.observer/filing/0000950170-23-028350.json
- Plain text: https://secwatch.observer/filing/0000950170-23-028350.txt

## Key facts
- Material Agreements
  Orthofix Medical Inc. amended Second Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and certain lender parties valued at $175 million (effective 2023-06-13).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: JPMorgan Chase Bank, N.A., as administrative agent, and certain lender parties
  - Value: $175 million
  - Effective: 2023-06-13
  source text: On June 13, 2023, Orthofix Medical Inc. (the “Company”) and certain of its wholly-owned subsidiaries entered into a Limited Consent, Limited Waiver and Second Amendment to Second Amended and Restated Credit Agreement (the “Consent and Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lender parties thereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000095017023028350/0000950170-23-028350-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.